Skip to content
TrialScanner

NCT05954143

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2TerminatedBOLTLead

Registry record

Lead sponsor
Bolt Biotherapeutics, Inc.
Conditions
Metastatic Breast Cancer; HER2-positive Breast Cancer
Primary completion
Sep 20, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05954143 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05954143: Trial of BDC-1001 +/... | TrialScanner